Selected article for: "current study and SARS acute respiratory syndrome"

Author: Majnooni, Mohammad Bagher; Fakhri, Sajad; Bahrami, Gholamreza; Naseri, Maryam; Farzaei, Mohammad Hosein; Echeverría, Javier
Title: Alkaloids as Potential Phytochemicals against SARS-CoV-2: Approaches to the Associated Pivotal Mechanisms
  • Cord-id: fsdx1r7m
  • Document date: 2021_5_13
  • ID: fsdx1r7m
    Snippet: Since its inception, the coronavirus disease 2019 (COVID-19) pandemic has infected millions of people around the world. Therefore, it is necessary to find effective treatments against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), as it is the viral source of COVID-19. Alkaloids are one of the most widespread plant-derived natural compounds with prominent antiviral effects. Accordingly, these phytochemicals have been promising candidates towards discovering effective treatments fo
    Document: Since its inception, the coronavirus disease 2019 (COVID-19) pandemic has infected millions of people around the world. Therefore, it is necessary to find effective treatments against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), as it is the viral source of COVID-19. Alkaloids are one of the most widespread plant-derived natural compounds with prominent antiviral effects. Accordingly, these phytochemicals have been promising candidates towards discovering effective treatments for COVID-19. Alkaloids have shown potential anti-SARS-CoV activities via inhibiting pathogenesis-associated targets of the Coronaviridae family that are required for the virus life cycle. In the current study, the chemistry, plant sources, and antiviral effects of alkaloids, as well as their anti-SARS-CoV-2 effect with related mechanisms, are reviewed towards discovering an effective treatment against COVID-19.

    Search related documents:
    Co phrase search for related documents
    • acanthaceae cusia and acute respiratory syndrome: 1
    • acceptable interaction and active site: 1
    • active site and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active site and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active site and lopinavir darunavir: 1
    • active site and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • activity assess and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • activity assess and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • acute respiratory and admet property: 1, 2, 3
    • acute respiratory and long chain: 1, 2, 3, 4, 5, 6, 7, 8
    • acute respiratory and lopinavir darunavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute respiratory syndrome and admet property: 1, 2
    • acute respiratory syndrome and long chain: 1, 2, 3, 4, 5, 6, 7
    • acute respiratory syndrome and lopinavir darunavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14